Regarding to the prevalence of breast cancer subtypes, distribution of HER2 and triple-negative subtypes is the most homogeneous among LATAM countries (ranging from 4.8%–18% and 13%–21.3%, respectively), contrasting to frequencies of luminal A (25.8%–76.6%) and luminal B tumours (7.2%–46.1%) (Figure 1). Here, ERBB2 is linked to breast cancer.